Table 2 Composition of principal component analysis (PCA) factors
From: Multi-dimensional characterization of prediabetes in the Project Baseline Health Study
Factor 1 | Sit/rise score (0.60), one-leg balance (0.53), 6-minute walk (0.44), body mass index (BMI) (-0.68), waist circumference (− 0.71) |
Factor 2 | Forced vital capacity (FVC) (0.81), diffusing capacity for carbon monoxide (DLCO) (0.79), forced expiratory volume (FEV1) (0.78), hand grip strength (0.75), hemoglobin (0.67), hematocrit (0.65), red blood cells (abs) (0.61), 6-min walk (0.59), sex (− 0.77) |
Factor 3 | Smoking (0.74), selection for high-risk lung cancer cohort (0.61), selection for high-risk cardiovascular disease (CVD) cohort (0.44), vitamin D (− 0.42) |
Factor 4 | Neutrophils (%) (0.96), neutrophil/lymphocyte ratio (0.87), neutrophils (absolute count) (0.68), lymphocytes (absolute count) (− 0.48), lymphocytes (%) (− 0.96) |
Factor 5 | Calcium (0.80), albumin (0.76), serum protein (0.68) |
Factor 6 | White blood cells (WBC) (0.88), lymphocytes (0.79), neutrophils (0.66), monocytes (0.45) |
Factor 7 | Average retinal nerve fiber layer (RNFL) thickness (0.95), specific RNFL thicknesses: inferior quadrant (0.86), superior quadrant (0.82), nasal quadrant (0.70), total macular volume (0.59) |
Factor 8 | Mean corpuscular hemoglobin (MCH) (0.97), mean corpuscular volume (MCV) (0.89), mean corpuscular hemoglobin concentration (MCHC) (0.62), red blood cells (RBC) (− 0.47) |
Factor 9 | HbA1c (0.84), diabetes (0.80), glucose (0.77), selection for high-risk CVD cohort (0.47) |
Factor 10 | Left ventricular ejection fraction (LVEF) (0.93), left ventricular inner dimension end systole (LVIDs) (− 0.53) |
Factor 11 | Urine creatinine (0.88), specific gravity (0.87), urine albumin (0.81), pH (− 0.49) |
Factor 12 | Total cholesterol (0.94), LDL cholesterol (0.89) |
Factor 13 | Ratio of FEV1 and FVC (0.66), oxygen saturation (0.41), chronic obstructive pulmonary disease (COPD) (− 0.59) |
Factor 14 | Sodium (0.83), chloride (0.79) |
Factor 15 | Coronary artery disease (CAD) (0.79), history of myocardial infarction (MI) (0.78), coronary artery calcium (0.62) |
Factor 16 | Eosinophils (%) (0.95), eosinophils (abs) (0.95) |
Factor 17 | Serum creatinine (0.81), chronic kidney disease (CKD) (0.57), estimated glomerular filtration rate (eGFR) (− 0.69) |
Factor 18 | Aspartate transaminase (AST) (0.92), alanine transaminase (ALT) (0.88) |
Factor 19 | General anxiety disorder-7 (GAD-7) (0.88), patient health questionnaire-9 (PHQ-9) (0.86) |
Factor 20 | Basophils (%) (0.86), basophils (abs) (0.86) |
Factor 21 | Center subfield thickness (eye imaging) (0.77), vitreoretinal interface abnormalities (0.67), total macular volume (0.45) |
Factor 22 | Reticulocytes (%) (0.93), reticulocytes (abs) (0.92) |
Factor 23 | Platelets (0.66), mean platelet volume (− 0.85) |
Factor 24 | Alcohol use identification test-C (AUDIT-C) score (0.51) |
Factor 25 | Left ventricular mass index (LVMI) (0.65), left ventricular inner dimension end diastole (LVIDd) (0.60), left ventricular inner dimension end systole (LVIDs) (0.48), pulse (− 0.53) |
Factor 26 | Left ventricular cardiac index (0.90), left ventricular cardiac output (0.83), pulse (0.40) |
Factor 27 | Monocytes (%) (0.82), monocytes (abs) (0.75) |
Factor 28 | Thyroid-stimulating hormone (TSH) (0.60) |
Factor 29 | Systolic blood pressure (0.85), diastolic blood pressure (0.84) |
Factor 30 | Potassium (0.73) |
Factor 31 | Atrial fibrillation (0.44), selection for high-risk breast/ovarian cancer cohort (− 0.53) |
Factor 32 | Heart failure (0.71), C-reactive protein (CRP) (0.49) |
Factor 33 | Stroke (0.75) |